学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
Menu
报名参会

已确认嘉宾Normal Guest

周彩存 主任

上海市肺科医院

周彩存 主任

周彩存,主任医师,医学博士,博士生导师。现任同济大学医学院肿瘤研究所所长,肿瘤学系主任,上海市肺科医院肿瘤科主任,肺癌免疫研究室主任,临床药理机构主任。《肿瘤》、《国际呼吸杂志》、《中德临床肿瘤学》、《中国肺癌杂志》、《中国癌症杂志》、《癌症》等杂志编委。1987-1998:安徽省蚌埠医学院附属医院住院医生、主治医师、讲师、副主任医师、副教授、科副主任;1990-1991:世川医学奖学金6期生在日本国立东京病院研修1年1994-1995:世川医学奖学金第3期特别研究者在日本国立东京病院研究院1年,2001-现在:上海市肺科医院肿瘤科主任医师、科主任,2002-现在:上海市肺科医院肺癌免疫研究室主任,2002.5-2002.11:美国MDAnderson癌中心访问学者(Visiting Scientist),2005.6-现在:同济大学教授,博士生导师,肿瘤所所长,肿瘤学系主任。承担国家863课题1项,国家自然科学基金2项,上海抗科委重大攻关项目2项,参加国家十一五攻关课题2项;主要从事肺癌早期诊断、综合治疗、靶向治疗和个体化治疗,肿瘤的分子显像,噬菌体疫苗。


主要发表论文与著作: 

Zhang G, Cheng R, Zhang Z, Jiang T, Ren S, Ma Z, Zhao S, Zhou C, Zhang J.Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Sci Rep. 2017 Feb 17;7:42979. doi: 10.1038/srep42979.


Chen K, Zhou F, Shen W, Jiang T, Wu X, Tong X, Shao YW, Qin S, Zhou C. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. J Thorac Oncol. 2017 Jan 16. pii: S1556-0864(17)30010-2.


Wang Q, Cheng N, Li X, Pan H, Li C, Ren S, Su C, Cai W, Zhao C, Zhang L, Zhou C. Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma. Oncotarget. 2017 Jan 10;8(2):2558-2567.


Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 Feb;12(2):194-207


He Y, Bunn PA, Zhou C, Chan D. KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. Oncotarget. 2016 Dec 13;7(50):82104-82111.


Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, Chuai S, Fei K, Zhou C, Hirsch FR. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. J Clin Oncol. 2015 Nov 10;33(32):3701-9.


Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204.


Zhou F, Zhou C. Necitumumab for patients with non-squamous NSCLC: uninspiring results. Lancet Oncol. 2015 Mar;16(3):246-7.


Zhou F, Chen X, Zhou C. Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drug. J Clin Oncol. 2015 Feb 10;33(5):523-4.


Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22.


Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. 


Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010 Aug;11(8):733-40.


Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest. 2010 Dec;28(10):1078-83.


Su C, Su B, Tang L, Zhao Y, Zhou C.Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cells. Cancer Invest. 2007;25(7):542-9.

邀请函

下载邀请函

赞助企业

大会咨询
姓名 *

E-mail*

电话: *

消息: *

×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: